Search This Blog

Monday, September 30, 2019

Spending Variation ‘Substantial’ Between Providers in Same Specialty

A report indicates that variation among providers affects spending on “medications, labs and radiology.”

Behavioral factors by doctors contribute to significant cost variations, even among the same type of patients, according to an Illumicare report released Tuesday morning.
The analysis of 15 sub-specialty groups with the largest cost variations found that the most significant factor was “what type of spender a patient’s provider is,” with cardiology and OB/GYN specialists leading the way.
Between the 25th and 75th percentiles, there was a $5,438 variation among pediatric hematology-oncologists, a difference of $3,885 among OB/GYN orders of cesarean sections without complications or comorbidities, and almost a $3,000 difference among OB/GYN orders on vaginal delivery without complicating diagnosis.
G.T. LaBorde, CEO of IllumiCare, told HealthLeaders that the purpose of the report was to communicate to the broader healthcare market about how much variation exists among doctors taking care of the same group of patients.
“What frustrates so many [healthcare executives] is when they say to a cardiologist, ‘Your patients are staying 1.2 days longer,'” LaBorde said. “Telling the cardiologist that isn’t insightful to them, it doesn’t help them understand the behavior that might be aberrant that leads to a longer length of stay. It only becomes actionable if [CFOs] can get so discreet that they can say, ‘Well, in this scenario, you’re the only provider that uses this drug,’ or ‘You tend to order this lab test more frequently than your peers.'”
“If a CFO can get that discreet, they can get to a point where they start changing behaviors which can change outcomes.”

The Illumicare report states that it should be “alarming” for health systems to see such substantial cost variations arising from standard medical procedures, which reinforces the need to address the issue with providers.
Ordering medications, lab tests and radiological exams were highlighted as the primary pain points for cost variations within a sub-specialty.
In one example from the report, cardiologists at three separate hospitals were analyzed on the basis of medications ordered for patients.
Thirty-three medications were ordered by cardiologists at all three hospitals, whereas 54 medications were ordered by cardiologists at only one hospital.
https://www.healthleadersmedia.com/finance/spending-variation-substantial-between-providers-same-specialty

Servier acquires lymphoma treatment PIXUVRI from CTI BioPharma

Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.
“The acquisition of PIXUVRI is an important step towards Servier’s long-term strategy to become a key player in oncology. Within oncology, one of our key focuses is hematology, and we now have two medicines that are marketed globally alongside a strong and innovative pipeline of drug candidates which includes CAR-T therapies,” said Claude Bertrand, Executive VP, Global Head of R&D at Servier. “As part of our strategy, we are committed to invest 50% of our R&D budget in oncology.”
https://www.marketscreener.com/news/Servier-acquires-non-Hodgkin-B-cell-lymphoma-treatment-PIXUVRI-pixantrone-from-CTI-BioPharma-s–29317108/

AstraZeneca Update on US regulatory review of PT010 in COPD

AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for PT010 (budesonide/glycopyrronium/formoterol fumarate), an inhaled triple-combination therapy and potential new medicine for patients with chronic obstructive pulmonary disease (COPD).
The NDA submitted to the FDA by AstraZeneca included data from the Phase III trial KRONOS. The Company will now work closely with the FDA regarding next steps, including submitting for review recent results from the second positive Phase III trial, ETHOS, which was not completed at the time the NDA was submitted.
PT010 was approved in Japan (https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html) in June 2019 as Breztri Aerosphere, a triple-combination therapy to relieve symptoms of COPD. PT010 is under regulatory review in China where it has been granted priority review by the National Medical Products Administration, and is also under regulatory review in the EU.
https://www.marketscreener.com/ASTRAZENECA-4000930/news/AstraZeneca-Update-on-US-regulatory-review-of-PT010-in-COPD-29317116/

Three pharmacies now pulling Zantac over FDA alert

Three major pharmacies are now pulling Sanofi’s (NASDAQ:SNY) heartburn medication Zantac off the shelves, after an FDA alert about potential low levels of a probable human carcinogen.
CVS (NYSE:CVS) had previously pulled the drug, and Walgreens (NASDAQ:WBA) and Rite Aid (NYSE:RAD) have joined in by removing the medication.
The FDA has said some ranitidine medicines including Zantac contain NDMA at low levels (levels that barely exceed amounts you might expected to find in common foods, it says).
There’s no recall of the medication, but all three pharmacies are accepting it for returns.
https://seekingalpha.com/news/3502763-three-pharmacies-now-pulling-zantac-fda-alert

Bristol-Myers Squibb (BMY) Presents At ESMO Congress 2019 – Slideshow

The following slide deck was published by Bristol-Myers Squibb Company in conjunction with this event.
125
ESMO 2019

Dementia Outcomes Improved With Supportive Care

Dementia patients’ quality of life improved over 12 months with team-based telephone and Internet support, a survey of dementia caregivers in the Care Ecosystem randomized trial showed.
Care delivered by a trained, unlicensed care team navigator and managed by an advanced-practice nurse, a social worker, and a pharmacist improved multiple facets of care, reported Katherine Possin, PhD, of the University of California San Francisco, and coauthors in JAMA Internal Medicine.
These included measures of patient quality of life, emergency department visits, caregiver depression, and caregiver burden.
“This study demonstrates that effective phone-based dementia care that addresses the needs of the person with dementia and the caregiver can be provided from a hub across large geographic areas, irrespective of the patients’ healthcare system affiliations,” Possin told MedPage Today.
“The Care Ecosystem addresses gaps in our healthcare system around dementia,” she continued. “While the Care Ecosystem won’t cure dementia, it changes the experience of dementia for both the patients and the caregivers, so that they may live as well as possible.”
A model like the Care Ecosystem can expand the reach of the dementia specialist workforce, Possin added. “We work at an academic medical center, where we have a lot of dementia specialists, and we are able to provide high-quality dementia care,” she noted. “But many people living with dementia in this country have limited or no access to dementia specialists because of where they live or because it is hard for them to travel to appointments.”
Earlier data from the Care Ecosystem research group showed that caregiver and dementia health were intertwined: dementia patients were nearly twice as likely to use an emergency department if their caregiver had depression, for example.
“Dementia is a public health challenge, a family disease, and a major strain on our healthcare system,” observed Jennifer Tjia, MD, MSCE, of the University of Massachusetts in Worcester, in an accompanying editorial. “Possin and colleagues have provided evidence that achieving the goals of the triple aim of improving care, health outcomes, and reducing cost can be met by providing dementia training to clinically supervised, unlicensed care team navigators in a scalable way.”
The single-blind, pragmatic Care Ecosystem trial was conducted in California, Nebraska, and Iowa in urban (San Francisco and Omaha) and rural settings. It randomized 780 dyads of dementia patients and caregivers — 512 to the Care Ecosystem intervention and 268 to usual care — from March 2015 to February 2017, tracking each dyad for 1 year.
All eligible patients had a dementia diagnosis from a treating provider and were enrolled in or eligible for Medicare or Medicaid. About half (49.8%) of patients had mild dementia; 28.7% had dementia, and 21.5% had severe dementia. Participants were informed of their randomization result and continued to receive services from other healthcare professionals throughout the study.
In the Care Ecosystem group, patients and caregivers received telephone-based, collaborative care from a team of dementia specialists. The team navigator was an unlicensed, trained guide who served as the primary point of contact for patients and caregivers under nurse supervision. Navigators called dyads approximately monthly; the number of telephone calls averaged 15.3 per dyad over 12 months. The nurse, social worker, and pharmacist were available for situations beyond the navigator’s scope, including safety concerns, behavioral symptoms, or complex legal and financial circumstances.
In the usual care group, participants were offered contact information for the Family Caregiver Alliance, the Alzheimer’s Association, and Area Agencies on Aging. They also were sent quarterly newsletters with general dementia-related articles and word games.
All outcomes were based on caregivers’ answers to telephone survey questions. The primary outcome measure was the Quality of Life in Alzheimer’s Disease (QOL-AD) score, which rated 13 aspects of patient quality of life — such as physical health, energy level, mood, memory, ability to do things for fun, and family relationships — on a four-point scale of poor, fair, good, or excellent.
For the primary outcome, caregivers reported that the Care Ecosystem improved patient quality of life (β 0.53, 95% CI 0.25-1.30; P=0.04). In secondary outcomes, the Care Ecosystem program was shown to do the following:
  • Reduce emergency department visits (β −0.14, 95% CI −0.29 to −0.01; P=0.04)
  • Decrease caregiver depression (β −1.14, 95% CI −2.15 to −0.13; P=0.03)
  • Lessen caregiver burden (β −1.90, 95% CI −3.89 to −0.08; P=0.046)
The effects of the Care Ecosystem on ambulance use and hospitalization were not significant, and the number needed to treat to prevent a single emergency department visit was 5. Comparing hospital and emergency services in the intervention group against expected use based on usual care data, the researchers calculated that the Care Ecosystem prevented 120 emergency department visits, 16 ambulance use events, and 13 hospitalizations over 12 months, providing an average cost savings of $600 per patient in these three services.
The study had several limitations, the researchers noted. Dyads were aware of their randomization, and the sample selected likely had fewer unmet needs than patients and caregivers in other populations. Economic outcomes were reported only for 12 months and were based on survey results.
“For many families, supportive dementia care such as the Care Ecosystem can change the experience of living with dementia,” Possin said. Supportive care can reduce stress and burdens on caregivers, she noted: “They are not alone, and can actually plan ahead for challenges that are coming, rather than feeling they are in a constant state of crisis.”
Last Updated September 30, 2019
This project was funded by the Department of Health and Human Services, Centers for Medicare & Medicaid Services, Global Brain Health Institute, National Institute on Aging, and National Institute on Neurological Disorders and Stroke.
The researchers reported relationships with the Centers for Medicare & Medicaid Services, National Institute on Aging, National Institute of Neurological Disorders and Stroke, Global Brain Health Institute, National Center for Advancing Translational Sciences, National Palliative Care Research Center, the John A. Hartford Foundation, the West Foundation, the Patient Centered Outcomes Research Institute, the American Academy of Hospice and Palliative Medicine, and Cornell University, as well as receiving UCSF grants.
The editorialist reported grants from the National Institutes of Health and the Cambia Health Foundation, personal fees from the Donaghue Foundation, and personal fees and nonfinancial support from CVS Health outside the study.

Cancer immunotherapy boom showing no sign of slowdown

  • Nearly twice as many cancer immunotherapies are now in development as were in testing two years ago, according to a new report from the Cancer Research Institute that highlights how the field has rapidly become a top target of drugmaker investment.
  • Just under 3,900 active drugs are now under preclinical or clinical study, up 91% from 2017, researchers from CRI found. A large portion of that growth came in cell therapy, with 797 new agents added to the industry’s pipeline over the past two years.
  • While roughly two-thirds of the drug candidates tracked by the institute are in preclinical stages, the number of immunotherapies in clinical testing grew significantly, too.
Cancer immunotherapy appears an investment that drugmakers can’t pass up.
The industry’s pipeline continues to expand rapidly, with more than 5,000 active immuno-oncology studies listed in the federal database clinicaltrials.gov.
Researchers at CRI counted 60% more organizations, including academic and research groups, were actively conducting testing of cancer immunotherapies in 2019 than in 2017, according to data published Friday in Nature Drug Discovery.
“This tremendous investment and commitment from different sectors have laid the foundation for 31 approvals by the FDA for IO drugs in the past 2 years,” the report’s authors wrote.
For companies like Merck & Co., Bristol-Myers Squibb and Roche, cancer immunotherapies are now a crucial part of revenue growth. But others, like Novartis, Celgene, Amgen and Eli Lilly, have expanded their pipelines in hopes of gaining ground on the field’s initial leaders.
Much of that research, however, focuses on similar biological pathways. There are more than 190 CD19-targeted immunotherapies in some form of testing, for example, as well as roughly 200 PD-1 and PD-L1 inhibitors.
Such overlap has raised concerns about duplicative efforts, as companies chase already proven drug classes.
Encouragingly, however, CRI found that 205 more targets were being studied in 2019 than in 2017, bringing the total ot 468 active targets. Some of the more common targets without an approved treatment include NY-ESO-1 and STAT3.
CRI’s numbers for clinical immunotherapy candidates are higher than the nearly 450 counted this year by IQVIA, a research group, although differences in definitions could explain the gap.
In its May 2019 report, IQVIA noted growth in the overall number of cancer drugs in development and found more than 212,000 Americans were treated with PD-1 or PD-L1 drugs last year, up nearly 100-fold from 2014.
https://www.biopharmadive.com/news/cancer-immunotherapy-research-growth-drug-study-oncology/563881/